THE US Food and Drug Administration has released a new draft guidance to aid industry in developing new drugs for use in "medication assisted treatment" (MAT) for opioid dependence.
The document explains the FDA's current thinking around passive-compliance modified-release "depot" buprenorphine products for injection or implantation.
See www.fda.gov.
The above article was sent to subscribers in Pharmacy Daily's issue from 23 Apr 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Apr 18